Veracyte's accelerating revenue growth (15.5% YoY in 2026Q2) and expanding gross margins (72.6%) demonstrate strong operational leverage, with operating income swinging from -$5.3M to $22.7M year-over-year. The company's capital-light model (CapEx/Revenue of 1...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.54+31.6% vs $0.41 | $150M+4.0% vs $145M |
Q2 2026 May 5, 2026 | $0.52+52.9% vs $0.34 | $139M+6.7% vs $130M |
Q1 2026 Feb 25, 2026 | $0.53+29.8% vs $0.41 | $141M+3.6% vs $136M |
Q4 2025 Nov 4, 2025 | $0.51+59.4% vs $0.32 | $132M+5.5% vs $125M |
Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) insider John Leite sold 4,015 shares of Veracyte stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $40.00, for a total transaction of $160,600.00. Following the sale, the insider owned 124,329 shares in the company, valued at approximately $4,973,160. This
Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,853 shares of the biotechnology company's stock after selling 49,301 shares during the quarter. Squarepoint Ops LLC's holdings in
Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,021 shares of the biotechnology company's stock after acquiring an additional 34,299 shares during the
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark VCYT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Veracyte, Inc. (VCYT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.81 | $3.66B | 55.87 | 16.01% | 12.83% | 5.34% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $410.35 | $58.77B | -269.97 | 35.9% | -7.11% | -11.73% | — | |
| $67.15 | $3.47B | -167.88 | 13.79% | 24.23% | 32.81% | — | |
| $63.78 | $651.32M | 17.72 | 20.23% | 27.3% | 13.02% | — | |
| $37.24 | $1.51B | 31.29 | 27.37% | 6.57% | 28.67% | — |
Veracyte, Inc. (VCYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Veracyte, Inc. (VCYT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 11, 2026·SEC
May 5, 2026·SEC
Get notified when VCYT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Veracyte, Inc. (VCYT) stock FAQ — growth, dividends, profitability & financials explained
Veracyte, Inc. (VCYT) reported $561.9M in revenue for fiscal year 2025. This represents a 21144% increase from $2.6M in 2011.
Veracyte, Inc. (VCYT) grew revenue by 16.0% over the past year. This is strong growth.
Yes, Veracyte, Inc. (VCYT) is profitable, generating $114.5M in net income for fiscal year 2025 (12.8% net margin).
Veracyte, Inc. (VCYT) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
Veracyte, Inc. (VCYT) generated $165.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
